Stocks of Halozyme Therapeutics - Current price, Where to buy? Chart
| Detail | Data |
|---|---|
| Stocks: | Halozyme Therapeutics |
| ompany Name: | Halozyme Therapeutics, Inc. |
| Ticker: | HALO |
| Exchange: | NasdaqGS |
| Outstanding stocks: | 127,054,000 |
| 24-hour Volume: | 1,006,441 |
| Industry: | |
| Sector: | |
| Number of Employees: | |
| Country: | |
| City: | |
| Address: |
| P/E Ratio: | Forward P/E | EPS: | Forward EPS | Book value per share | Market capitalization |
|---|---|---|---|---|---|
| 18.71 | 8.62 | 2.1 USD | 4.56 USD | 0.66 USD | 4,993,222,144.00 USD |
| P/E Ratio: | 18.71 |
|---|---|
| Forward P/E: | 8.62 |
| EPS: | 2.1 USD |
| Forward EPS: | 4.56 |
| Book value per share: | 0.66 USD |
| Market capitalization: | 4,993,222,144.00 USD |
Halozyme Therapeutics
Fundamental Indicators
| Indicator | Data |
|---|---|
| Total Revenue: | 829,252,992.00 USD |
| Net Income: | 281,593,984.00 USD |
| Price-to-Book (P/B) Ratio: | 59.46 |
| PEG Ratio: | 0.41 |
Note: The data is approximate, subject to change over time, and may not be current; however, we strive for the highest possible accuracy.
Analysts' predictions
| Analysts | Recommendation |
|---|---|
| Issued Recommendation: | According to our data, the recommendation issued for Halozyme Therapeutics stocks is: buy |
| Number of Analysts: | 9 |
| Highest Target Price: | 72 USD |
| Lowest Target Price: | 39 USD |
| Average Target Price: | 50 USD |
Note: The data is approximate. Recommendations and price forecasts for Halozyme Therapeutics stocks based on analysts' ratings may change over time. Some recommendations may already be outdated and may not be accurate. We strongly advise against buying and selling stocks based on analysts' recommendations!
Dividend
| Dividends | Value |
|---|---|
| Dividend Amount | According to our data, the company Halozyme Therapeutics is currently not paying dividends. |
| Annual Yield %: | - |
| Ex-dividend Date: | - |
| Average % Yield for 5 Years: | - |
| Payout Ratio: | - |
| Value of Last Dividend Paid: | - |
| Date of Last Dividend: | - |
The dividend is displayed for the entire calendar year, however, it is usually paid out quarterly in parts. Data may change!
Where to Buy Halozyme Therapeutics Stocks?
If you're interested in investing in Halozyme Therapeutics stocks and believe in their future growth, you can purchase them through stock brokers like XTB or eToro. To make buying easier, we've prepared a table with offers from these brokers, including quick purchase of Halozyme Therapeutics stocks through mobile apps with client support. In this table, you can compare brokers offering real Halozyme Therapeutics stocks. Brokers providing the option to buy real stocks (not CFDs) are identified by "Real Stocks" in the comparison table column.
| Broker | Platforms | Regulation | Min. Deposit | Deposits / Withdrawals | CopyTrader | Real Stocks | Website Link |
|---|---|---|---|---|---|---|---|
 |
Proprietary platform, social network + CopyTrader™ | 100 USD | Bank transfer, credit cards, Skrill, PayPal, Neteller |
 Go to eToro
|
|||
 |
xStation, mobile version | 10 USD | Credit cards, Skrill, bank transfer |
 Go to XTB
|
|
|
| xStation, mobile version | Proprietary platform, social network + CopyTrader™ |
|
Go to XTB
|
Go to eToro
|
More Information about Halozyme Therapeutics (HALO)
Revenues of 829,252,992.00 USD indicate room for growth and improvement for Halozyme Therapeutics. This presents an opportunity for further development. EBITDA of 416,929,984.00 USD reflects profitable operations with potential for further improvement for Halozyme Therapeutics. A higher debt-to-equity ratio of 18.27 indicates higher leverage for Halozyme Therapeutics compared to its equity, requiring cautious management. Gross margin of 67.59% shows that Halozyme Therapeutics efficiently manages costs and maintains a high share of revenues. This is a sign of a strong market position. Profit margin of 33.96% underscores Halozyme Therapeutics's efficiency in converting revenues into net income, which is crucial for its prosperity.
| Indicator | Value |
|---|---|
| Revenue, Debt, and Cash Flow | |
| Company Revenue: | 829,252,992.00 USD |
| EBITDA: | 416,929,984.00 USD - Positive EBITDA indicates profitable operations before interest, taxes, depreciation, and amortization. |
| Earnings Per Share: | 2.1 USD |
| Book Value Per Share: | 0.66 USD |
| Total Cash: | 336,000,000.00 USD |
| Total Cash per Share: | 2.65 USD |
| Total Debt: | 1,531,444,992.00 USD |
| Debt to Equity Ratio: | 18.27 |
| Quick Ratio: | 5.07 |
| Current Ratio: | 6.64 |
| Free Cash Flow: | 268,162,000.00 USD |
| Operating Cash Flow: | 388,571,008.00 USD |
| Company Margins | |
| Gross Margins: | 67.59 % |
| EBITDA Margins: | 50.28 % |
| Operating Margins: | 45.01 % |
| Profit Margins: | 33.96 % |
| Performance | |
| Return on Assets: | 11.9 % |
| Return on Equity: | 222.1 % |
| Earnings Growth (1 year): | 54.6% |
| Revenue Growth (1 year): | 26.7 % |
| Year-over-Year Quarterly Earnings Growth: | 48.0 % |
| Valuation | |
| Market Capitalization: | 4,993,222,144.00 USD |
| Enterprise Value: | 6,179,659,776.00 USD |
| EV/Revenue: | 7.452 |
| EV/EBITDA: | 14.822 |
| Number of Shares and Short Shares | |
| Float Shares: | 125,425,922 shares |
| Shares Outstanding: | 127,054,000 shares |
| Held Percent Insiders: | 0.01 % |
| Held Percent Institutions: | 100.10 % |
| Shares Short: | 8,238,441 |
| Shares Short Prior Month: | 8,201,639 |
| Date Short Interest: | 2024-04-15 |
| Shares Percent Shares Out: | 6.48 % |
| Short Ratio: | 8.73 |
| Beta: | 1.26 |
| Short Percent of Float: | 8.78 % |
| Předpokládaný počet akcií: | 127,054,000 |
Frequently Asked Questions (FAQ)
According to our data, Halozyme Therapeutics does not currently pay dividends, even in 2024.
Halozyme Therapeutics shares are traded on the stock exchange NasdaqGS under the ticker symbol: HALO. You can buy or trade them with a variety of stock brokers offering real stock trading services.
According to our data, there is a buy recommendation issued for Halozyme Therapeutics shares by a total of 9 analysts. The average target price prediction is 50 USD per share.
The total number of Halozyme Therapeutics shares on the exchange is 127,054,000.00, which, at the current market capitalization, values the company at 4,993,222,144.00 USD.
